Cempra, a biotech focused on bacterial infectious diseases, slumped 58% after the Food and Drug Administration rejected two drug applications related to its lead product, solithromycin. The applications applied to oral and intravenous versions of the drug aimed at treating community-acquired bacterial pneumonia, or CABP.